FATE - FATE THERAPEUTICS INC

QQQ $ 633.20 nm (nm)

DIA $ 475.83 $ -1.36 (-0.29 %)

SPY $ 684.43 nm (nm)

TLT $ 90.42 nm (nm)

GLD $ 371.67 $ 7.13 (1.96 %)

Previous Close

$ 1.29

Open

$ 1.35

Bid

$ 1.25 x 4,400

Ask

$ 1.53 x 100

Day's Range

$ 1.28 - $ 1.38

52 Week Range

$ 0.66 - $ 3.50

Volume

801,472

Average Volume

Market Cap

148.78M

Beta (5Y Monthly)

$ 2.22

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-12-2025	06-30-2025	10-Q
2	05-13-2025	03-31-2025	10-Q
3	03-05-2025	01-01-1970	10-K
4	11-12-2024	09-30-2024	10-Q
5	08-13-2024	06-30-2024	10-Q
6	05-09-2024	03-31-2024	10-Q
7	02-26-2024	12-31-2023	10-K
8	11-08-2023	09-30-2023	10-Q
9	08-08-2023	06-30-2023	10-Q
10	05-03-2023	03-31-2023	10-Q
11	02-28-2023	12-31-2022	10-K
12	11-03-2022	09-30-2022	10-Q
13	08-03-2022	06-30-2022	10-Q
14	05-04-2022	03-31-2022	10-Q
15	02-28-2022	12-31-2021	10-K
16	11-04-2021	09-30-2021	10-Q
17	08-04-2021	06-30-2021	10-Q
18	05-05-2021	03-31-2021	10-Q
19	02-24-2021	12-31-2020	10-K
20	11-05-2020	09-30-2020	10-Q
21	08-05-2020	06-30-2020	10-Q
22	05-11-2020	03-31-2020	10-Q
23	03-02-2020	12-31-2019	10-K
24	11-05-2019	09-30-2019	10-Q
25	08-06-2019	06-30-2019	10-Q
26	05-07-2019	03-31-2019	10-Q
27	03-05-2019	12-31-2018	10-K
28	11-01-2018	09-30-2018	10-Q
29	08-06-2018	06-30-2018	10-Q
30	05-10-2018	03-31-2018	10-Q
31	03-05-2018	12-31-2017	10-K
32	11-01-2017	09-30-2017	10-Q
33	08-14-2017	06-30-2017	10-Q
34	05-15-2017	03-31-2017	10-Q
35	03-16-2017	12-31-2016	10-K
36	11-07-2016	09-30-2016	10-Q
37	08-08-2016	06-30-2016	10-Q
38	05-09-2016	03-31-2016	10-Q
39	03-03-2016	12-31-2015	10-K
40	11-03-2015	09-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Wedbush Upgrades Fate Therapeutics to Outp...
10/27/2025 12:40:03

Wedbush analyst David Nierengarten upgrades Fate Therapeutics (NASDAQ:FATE) from Neutral to Outperform and raises the price ...

Needham Reiterates Hold on Fate Therapeuti...
10/27/2025 09:40:54

Needham analyst Gil Blum reiterates Fate Therapeutics (NASDAQ:FATE) from Hold to Hold.

Reported Sunday, Fate Therapeutics Present...
10/27/2025 06:37:45

As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythema...

Fate Therapeutics Appoints Kamal Adawi As ...
10/14/2025 12:05:04

12 Health Care Stocks Moving In Tuesday's ...
09/30/2025 17:06:34

Wells Fargo Maintains Equal-Weight on Fate...
08/13/2025 12:52:11

Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and lowers the price target from...

Fate Therapeutics Q2 EPS $(0.29) Beats $(0...
08/12/2025 20:17:59

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0...

Needham Reiterates Hold on Fate Therapeuti...
06/12/2025 12:27:54

Needham analyst Gil Blum reiterates Fate Therapeutics (NASDAQ:FATE) from Hold to Hold.

Fate Therapeutics Announces New And Update...
06/11/2025 13:02:32

All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve Primar...

Fate Therapeutics Reveals Phase 1 Data Pre...
05/28/2025 21:56:24

Barclays Maintains Overweight on Fate Ther...
05/14/2025 14:56:43

Barclays analyst Peter Lawson maintains Fate Therapeutics (NASDAQ:FATE) with a Overweight and lowers the price target from $...

4 Analysts Assess Fate Therapeutics: What ...
05/14/2025 14:00:41

Baird Maintains Neutral on Fate Therapeuti...
05/14/2025 13:14:28

Baird analyst Jack Allen maintains Fate Therapeutics (NASDAQ:FATE) with a Neutral and lowers the price target from $5 to $4.

Needham Reiterates Hold on Fate Therapeuti...
05/14/2025 11:31:55

Needham analyst Gil Blum reiterates Fate Therapeutics (NASDAQ:FATE) from Hold to Hold.

Fate Therapeutics Q1 EPS $(0.32) Beats $(0...
05/13/2025 20:12:11

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0...

Fate Therapeutics Wins Regenerative Medici...
04/14/2025 12:05:22

– Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue w...

Stifel Maintains Hold on Fate Therapeutics...
03/06/2025 15:59:11

Stifel analyst Benjamin Burnett maintains Fate Therapeutics (NASDAQ:FATE) with a Hold and lowers the price target from $5 to...

Wedbush Reiterates Neutral on Fate Therape...
03/06/2025 14:10:44

Wedbush analyst David Nierengarten reiterates Fate Therapeutics (NASDAQ:FATE) with a Neutral and maintains $5 price target.

Wells Fargo Maintains Equal-Weight on Fate...
03/06/2025 14:00:01

Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and lowers the price target from...

Needham Reiterates Hold on Fate Therapeuti...
03/06/2025 11:56:28

Needham analyst Gil Blum reiterates Fate Therapeutics (NASDAQ:FATE) from Hold to Hold.